



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Confirmation No.:

Sedgwick et al.

Group Art Unit:

Application Serial No.: 10/588,504

Examiner: Worley, C.K.

Filed: August 4, 2006

Atorney Docket No.: 015959.00015

For: Selection Markers Useful for Heterologous Protein Expression

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Date: December 1, 2006

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the information item(s) listed on the attached Form PTO-SB08b. Unless otherwise indicated herein, one copy of each item(s) is attached. respectfully requested that the information be expressly considered during the prosecution of this application, and that the item(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

\boxtimes	1. This Information Disclosure Statement is being filed (a) within three mont of the U.S. filing date, OR (b) before the mailing date of a first Office Action on the merits in the present application, OR (c) accompanies a Request for Continued Examination. No certification or fee is required.				
		This Information Disclosure Statement is being filed more than three month he U.S. filing date AND after the mailing date of the first Office Action on the , but before the mailing date of a Final Rejection or Notice of Allowance.			
		a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).			
		b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).			

TECH/468051.1

	c. A check in the amount of \$180.00 in payment of the fee under 37 CFR §1.17(p). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.				
Allowa the Inf amour charge	3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. Applicant(s) hereby petition(s) that the Information Disclosure Statement be considered. Attached is our check in the amount of \$180.00 in payment of the petition fee under 37 CFR §1.17(i)(1). Please charge any fee deficiency or credit any overpayment to Deposit Account No. 01-2300 as needed to ensure consideration of the disclosed information.				
	a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).				
	b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).				
4. Copies	The references were cited in a counterpart International Search Report. s of the references are not enclosed.				
	Respectfully submitted,				

in close

Richard V. Berman

Registration No. 39,107

Customer No. 004372 ARENT FOX PLLC 1050 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Tel: (202) 857-6000 Fax: (202) 638-4810

RJB/pdc

Enclosures: PTO/SB/08b, 23 references



Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Substitute	e for form 1449B/PTO	Complete if Known							
	INFO	RMATION DISCLOSURE	Application Number	10/588,504						
		EMENT BY APPLICANT	Filing Date	August 4, 2006						
	ואוט	Form PTO/SB/08b	First Named Inventor	Sedgwick		_				
		10111110/35/005	Art Unit							
			Examiner Name							
Sheet		1 of 2	Attorney Docket Numbe							
			ITERATURE DOCU							
Examiner Initials*	Cite No.1									
	_	"Toxins-Antitoxins: Plasmid Maintenance, Programmed Cell Death, and Cell Cycle Arrest," Hayes, Science, 301, 2003, pp. 1496-1499								
		"Studies on plasmid stability, cell metabolism and superoxide dismutase production by Pgk strains of Saccharomyces cerevisiae," Ayub et al., Appl. Microbiol Biotechnol, 37, 1992, pp. 615-620.								
		"A novel leader peptide which allows efficient secretion of a fragment of human interleukin 1ß in Saccharomyces cerevisiae," Baldari et al., The EMBO Journal, 6(1); 1987, pp. 229-234								
		"Transformation of yeast by a replicating hybrid plasmid," Beggs, Nature, 275, 1978, pp. 104-109								
		"Copy Number Modulation in an Autoselection System for Stable Plasmid maintenance in Saccharomyces cerevisiae," Compagno et al., Biotechnol. Prog., 9, 1993, pp. 594-599								
		"Selection of Yeast cells with a Higher Plasmid Copy Number in a Saccharomyces cerevisiae Autoselection System," Compagno et al., Yeast, 12, 1996, pp. 199-205								
		"Colocalization of sterol isomerase and sig Dussossoy et al., Eur. J. Biochem, 263, 19		asmic reticulum and nuclear e	nvelope level,"					
		"The Presence of a Defective LEU2 Gene on 2µ DNA Recombinant Plasmids of Saccharomyces cerevisiae Is Responsible for Curing and High Copy Number," Erhart et al., Journal of Bacteriology, 156(2), 1983, pp. 625-635								
		"Copy Number and the Stability of 2-µm Circle-Based Artificial Plasmids of Saccharomyces cerevisiae," Futcher et al., Journal of Bacteriology, 157(1), 1984, pp. 283-290								
		"Comparison of three expression systems for heterologous xylanase production by S. cerevisiae in defined medium," Görgens et al., Yeast, 21, 2004, pp. 1205-1217								
		"Engineering Yeast for Efficient Cellulose Degradation," Van Rensburg et al., Yeast, 14, 1998, pp. 67-76								
		"An autoselection system in recombinant <i>Kluyveromyces lactis</i> enhances cloned gene stability and provides freedom in medium selection," Hsich et al., Appl. Microbiol. Biotechnol. 49, 1998, pp. 147-152								
		"High Level of Expression of a Protective Antigen of Schistosomes in Saccharomyces cerevisiae," Loison et al., Yeast, 5, 1989, pp. 497-507								
		"Plasmid-Transformed URA3 Furi Double-Mutants of S. cerevisiae: An Autoselection System Applicable to the Production of Foreign Proteins," Loison et al., Bio/Technology, 4, 1986, pp. 433-437								
	_	"Enhancement of Cloned Gene Product Synthesis via Autoselection in Recombinant Saccharomyces cerevisiae," Napp et al., Biotechnology and Bioengineering, 41, 1993, pp. 801-810								
		"When a glycolytic gene on a yeast 2µORI-STB plasmid is made essential for growth its expression level is a major determinant of plasmid copy number," Piper et al., Current Genetics, 1990, pp. 119-123								
		"Complementation of the Saccharomyces cerevisiae srb1-1 mutation: an autoselection system for stable plasmid maintenance," Rech et al., Current Genetics, 21, 1992, pp. 339-344								
		"A new system for amplifying 2 μm plasmid copy number in Saccharomyces cerevisiae," Unternahrer et al., Molecular Microbiology, 5 (6), 1991, pp. 1539-1548								
		"Co-expression of a Phanerochaete chry endo-beta-1,4-glucanase gene in Sacchar 1996, pp. 246-250.	vsosporium cellobiohyo omyces cerevisiae," va	rolase gene and a Butyrivbrin Rensburg et al., Current Go	io fibrisolvens enetics, 30 (3),					
		"Plasmid Stability During Continuous Culture in a Saccharomyces cerevisiae Double Mutant Transformed by a Plasmid Carrying a Eukaryotic Gene," Marquet et al., Biotechnology Letters, 8(8), 1986, pp. 535.540								
		"Engineering yeast for high level expression," Fleer, Biotechnology, 3, 1992, pp. 486-496								
		"Double mutants of Saccharomyces cerevisiae harbour stable plasmids: stable expression of a eukaryotic gene and the influence of host physiology during continuous culture," Marquet et al., Journal of Biotechnology, 6, 1987, pp. 135-145								
		"Over-expression of the Saccharomyces subtilis endo-ß-1,3-1,4-glucanase gene an van Rensburg et al., Journal of Biotechnology	d the <i>Butyrivibrio fibrise</i> ogy, 55 , pp. 43-53 (199	olvens endo-ß-1,4-glucanase g	n the bacillus ene in years,"					
Examiner Signature			Date Consider	ed						

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code. ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

